ALPMF - Astellas Pharma's Xtandi OK'd in China for non-metastatic prostate cancer

The China National Medical Products Administration has approved Astellas Pharma's (ALPMF) XTANDI (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.This is the second approved indication in China for enzalutamide, which is already available for adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

For further details see:

Astellas Pharma's Xtandi OK'd in China for non-metastatic prostate cancer